epigallocatechin-3-gallate
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03928847 | Dec 2017 → May 2019 | idiopathic pulmonary fibrosis | Hal Chapman | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06524609 | Nov 2023 → Nov 2024 overdue | chemotherapy-induced neuropathy | Han Xi Zhao | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00262743 | Aug 2005 → May 2010 | leukemia | Mayo Clinic | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04553666 | Apr 2021 → Aug 2023 | — | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT02015312 | Apr 2013 → Oct 2017 | AL amyloidosis | Florian Michel | Completed | No outcome recorded |
| Phase 2 | NCT00951964 | Oct 2010 → Jul 2013 | epidermolysis bullosa dystrophica | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT01394796 | May 2010 → Feb 2011 | Down syndrome | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01222000 | Oct 2010 → Mar 2012 | lamellar ichthyosis | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00525668 Comparator | Sep 2007 → Nov 2012 | relapsing-remitting multiple sclerosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epigallocatechin 3 Gallate | “Polyphenon E with a standardized dose of epigallocatechin-3-gallate (EGCG) was administered using the standard phase I design with three to six patients per dose level (range,...” PMID 19470922 ↗ May 20099“OBJECTIVE: To assess the safety and efficacy of epigallocatechin-3-gallate (EGCG) add-on to glatiramer acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS).” PMID 33762428 ↗ Mar 2021 “Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.” PMID 27015660 ↗ Mar 2016 “Recent studies showed that the epigallocatechin-3-gallate (POLYPHENON E®), extracted from green tea increases the differentiation of the normal human keratinocytes” NCT01222000 ↗ “Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)” NCT00951964 ↗ “Dietary Supplement: Epigallocatechin-3-gallate (EGCG)” NCT01394796 ↗ |
| Known as | EGCG | “Polyphenon E with a standardized dose of epigallocatechin-3-gallate (EGCG) was administered using the standard phase I design with three to six patients per dose level (range,...” PMID 19470922 ↗ May 20095“OBJECTIVE: To assess the safety and efficacy of epigallocatechin-3-gallate (EGCG) add-on to glatiramer acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS).” PMID 33762428 ↗ Mar 2021 “Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)” NCT04553666 ↗ “epigallocatechin-3-gallate (EGCG), a green tea extract” PMID 27015660 ↗ Mar 2016 “Dietary Supplement: Epigallocatechin-3-gallate (EGCG)” NCT01394796 ↗ “Epigallocatechin-3-gallate (EGCG) capsules” NCT03928847 ↗ |
| Known as | epigallocatechin gallate | “Polyphenon E with a standardized dose of epigallocatechin gallate (EGCG) (2000 mg per dose) was administered twice daily.” PMID 22760587 ↗ Jul 20121“epigallocatechin-gallate (Sunphenon)” NCT00525668 ↗ |
| Known as | Polyphenon E | “Recent studies showed that the epigallocatechin-3-gallate (POLYPHENON E®), extracted from green tea increases the differentiation of the normal human keratinocytes” NCT01222000 ↗1“Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)” NCT00951964 ↗ |
| Known as | Sunphenon | “epigallocatechin-gallate (Sunphenon)” NCT00525668 ↗ |
| Action | Inhibit | “Egcg, a dyrk1a Inhibitor” NCT01394796 ↗ |
| Route | Oral | “Patients receive oral green tea extract (Polyphenon E)” NCT00262743 ↗ |
| Target | DYRK1A | “modulation properties of the major catechin in green tea, epigallocatechin-3-gallate (EGCG), on dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene...” NCT01394796 ↗ |